Development of Novel Antimicrobial Resistance Agents

新型抗菌药物耐药剂的开发

• 批准号: 7696715
• 金额: $ 1133.05万
• 依托单位: ACHAOGEN, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7696715
• 关键词: Development; Novel; Antimicrobial; Resistance; Agents

This contract supports the advanced development of novel aminoglycoside agents as broad spectrum therapeutics for the treatment of antimicrobial resistant category A and B bacterial infections. The activities supported by this contract include preclinical and clinical development that fall into lead optimization and clinical candidate selection, IND-enabling activities; manufacturing activities; clinical activities; and animal study activities. Additional objectives include the identification and preclinical development of a nephroprotectant technology for co-administration with an animoglycoside agent and validation of a novel in vitro assay for the early stage detection of nephrotoxicity potential among small molecule drug candidates.

该合同支持新型氨基糖苷类药物的先进开发，作为治疗抗菌药物耐药性 A 类和 B 类细菌感染的广谱疗法。该合同支持的活动包括临床前和临床开发，涉及先导化合物优化和临床候选药物选择、IND支持活动；制造活动；临床活动；和动物研究活动。其他目标包括鉴定和临床前开发与茴香糖苷类药物共同给药的肾保护剂技术，以及验证用于早期检测小分子候选药物中肾毒性潜力的新型体外测定。